ask our doctors

Renal Cell Carcinoma

Get the facts on Renal Cell Carcinoma treatment, diagnosis, staging, causes, types, symptoms. Information and current news about clinical trials and trial-related data, Renal Cell Carcinoma prevention, screening, research, statistics and other Renal Cell Carcinoma related topics. We answer all your qestions about Renal Cell Carcinoma.

Question: What are the lastest advances in treatments for renal cell carcinoma (stage 3)? My best friend has recently been diagnosed with Renal cell carcinoma. Early diagnosis suggest that the cancer has metastasized and spread to the lymph nodes, but has not spread to any other organs. I am interested to know if anyone knows whom are the worlds experts in renal cell carcinoma (RCC) (both medical and academic experts). Unfortunately we are British and so the only likelyhood of my friend getting the latest drugs is by partaking in a clinical trial (NICE, the body that regulates which drugs are purchased for UK NHS patients generally do not pay out for the latest expensive treatments) . I would like to know therefore is anybody reading this post who is involved in organising/running clinical trials for drugs to treat RCC who might be able to discuss further options. My friend shows otherwise no symptoms at all apart from once urinating blood. He is in otherwise good health and is aged 33.

Answer: I suggest he contact Shands hospital in Houston.


Renal Cell Carcinoma News

Argos Therapeutics Announces New Data Demonstrating Prolonged Overall Survival ...

PR Newswire (press release)
... announced that updated results from an open label Phase 2 study of its Arcelis? immunotherapy, AGS-003, in combination with sunitinib in patients with unfavorable risk, metastatic renal cell carcinoma (mRCC), had demonstrated prolonged survival.
 

Cabozantinib Shows Encouraging Activity in Heavily Pretreated Patients With ...

MarketWatch (press release)
Exelixis, Inc. /quotes/zigman/82395/quotes/nls/exel EXEL +5.25% today reported preliminary data from a cohort of heavily pretreated patients with metastatic refractory renal cell carcinoma (RCC) participating in an ongoing phase 1b trial of ...
 

Cabozantinib Shows Encouraging Activity in Heavily Pretreated Patients With ...

EON: Enhanced Online News (press release)
(EON: Enhanced Online News)--Exelixis, Inc. (NASDAQ:EXEL) today reported preliminary data from a cohort of heavily pretreated patients with metastatic refractory renal cell carcinoma (RCC) participating in an ongoing phase 1b trial of cabozantinib.
 

Kuwait Times

FDA clears Pfizer drug for advanced kidney cancer
Wall Street Journal
 

New Oral Kinase Inhibitor Axitinib Approved for Advanced Renal Cancer

Pharmacy Practice News
The FDA has approved the oral kinase inhibitor axitinib (Inlyta, Pfizer) for treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy, according to press releases from the FDA and Pfizer.
 

Twelve-year survival after multiple recurrences and repeated metastasectomies ...

UroToday
BACKGROUND: Metastatic renal cell carcinoma (RCC) presents a therapeutic challenge for clinicians because of the unpredictable clinical course, resistance to chemotherapy or radiotherapy and the limited response to immunotherapy.
 

Growth pattern of renal cell carcinoma (RCC) in patients with delayed surgical ...

UroToday
PURPOSE: Few studies have evaluated the growth pattern of renal cell carcinoma (RCC) in patients with delayed treatment. This report investigated the growth rate and stage progression of incidentally discovered RCC following a long period of active ...
 

Cabozantinib Shows Encouraging Activity In Pretreated Patients With Advanced RCC

NASDAQ
(RTTNews.com) - Exelixis, Inc. (EXEL) reported preliminary data from a cohort of heavily pretreated patients with metastatic refractory renal cell carcinoma, or RCC, participating in an ongoing phase 1b trial of cabozantinib.
 

Organ-preserving renal tumor surgery for renal cell carcinoma ?T1b ...

UroToday
Current data, however, suggest that approximately 60% of patients with T1b tumors are treated by radical nephrectomy. PATIENTS AND METHODS: We performed a retrospective analysis of 320 patients with renal cell cancer who underwent organ sparing ...
 

Bionomics Limited : BNC105 RENAL CANCER TRIAL DATA PRESENTED AT ASCO-GU

4-traders (press release)
Bionomics is conducting a US multi-centre Phase II clinical trial of BNC105 in combination with everolimus (Afinitor) in patients with metastatic Renal Cell Carcinoma (RCC). Afinitor is an mTOR inhibitor, which is used as a treatment after patients ...